NCT03119428View on ClinicalTrials.gov

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Locally Advanced CancerMetastatic Cancer
Interventions
DRUG

OMP-313M32

OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.

DRUG

Nivolumab

Human IgG4 anti-PD-1 monoclonal antibody

Trial Locations (5)

27710

Durham, Durham

37203

Nashville, Nashville

73104

Oklahoma, Oklahoma City

84112

Salt Lake City, Salt Lake City

85258

Scottsdale, Scottsdale

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT03119428 - A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter